|2.||Chronic Kidney Failure (Chronic Renal Failure)
|4.||Kidney Diseases (Kidney Disease)
|1.||Locatelli, Francesco: 46 articles (01/2016 - 07/2002)|
|2.||Nemeth, Elizabeta: 45 articles (01/2016 - 04/2003)|
|3.||Ganz, Tomas: 45 articles (01/2016 - 11/2002)|
|4.||Lang, Florian: 43 articles (01/2015 - 11/2003)|
|5.||Macdougall, Iain C: 29 articles (05/2013 - 05/2002)|
|6.||Ferrucci, Luigi: 26 articles (11/2015 - 08/2003)|
|7.||Singh, Ajay K: 26 articles (09/2015 - 01/2005)|
|8.||Semba, Richard D: 26 articles (07/2015 - 01/2002)|
|9.||Rivella, Stefano: 25 articles (09/2015 - 04/2003)|
|10.||Del Vecchio, Lucia: 24 articles (01/2016 - 01/2003)|
02/01/2013 - "Although the anemia in the three treated groups was resolved after 3 and 12 weeks of oral iron therapy, we conclude that the regimen of two doses per week is the most effective in resolving anemia with less cost and fewer side effects."
04/15/2011 - "Most anemias were asymptomatic and improved with iron/multivitamin supplementation and cessation of ZDV exposure. "
05/01/2004 - "The regimen with iron administered daily is still the best option for treating anemia. "
02/15/2003 - "The combination of IPT and iron supplementation was most effective in the treatment of mild anemia. "
09/01/2001 - "Paired analysis of 875 patients present in 1996 and 1998 showed that, although there was a marked increase in the use of IV iron, the improvement in anemia was modest, and there was evidence for increased iron accumulation. "
05/01/2001 - "The most promising results have been noted in the treatment of erythropoietin-resistant anemia. "
09/04/1991 - "[Erythropoietin is highly effective in renal anemia but should be prescribed with caution]."
02/01/2007 - "Recombinant human erythropoietin (rhEpo) has proven to be remarkably safe and effective for treatment of anemias, primarily those secondary to renal disease and malignancy. "
01/01/2006 - "The only proven effective prevention of RBV-induced anemia is the concomitant administration of erythropoietin. "
05/01/1997 - "Recombinant human erythropoietin (rHuEPO) is used extensively in anemic patients on dialysis and other patients and is regarded as very safe and effective in the management of anemia in these patients. "
09/01/2007 - "Children who benefited the most from anthelmintic treatment in terms of increased hemoglobin concentrations were those who had anemia at baseline and those with highly positive microhematuria scores at baseline. "
07/01/1980 - "Anemia is the abnormality most likely to be encountered, and investigation of a marginal reduction in the hemoglobin level of an elderly patient may be rewarded with a specific diagnosis of a disease that can be effectively treated, at least for a time."
10/01/2013 - "To improve patients' outcomes, further study is required to more fully explore the risk of anemia, optimal hemoglobin level, and the risk and efficacy of RBC transfusion. "
01/01/1996 - "In univariate analysis, factors associated with poor survival were stage IV (Ann Arbor staging system), anemia (hemoglobin level less than 10g/dl), bone marrow involvement, two or more extranodal sites, and failure in induction of complete remission (CR) in the entire course. "
05/01/1991 - "After operation, the anemia markedly improved while rHuEPO was administered, but the hemoglobin levels decreased rapidly when the administration was terminated. "
|4.||Epoetin Alfa (Epogen)FDA Link
04/01/1993 - "For most patients, therapy with Epoetin alfa reverses anemia and provides them with many benefits, including an improved quality of life. "
08/01/2003 - "Epoetin alfa has proven efficacy and safety in correcting anemia and improving QOL based on numerous clinical studies and over a decade of clinical practice. "
04/01/1992 - "Epoetin alfa therapy has been proven effective in treating anemia in dialysis patients; it increases the hematocrit (HCT) and improves the quality of life. "
02/01/2006 - "Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl."
06/01/2004 - "Once-weekly epoetin alfa therapy is safe and effective for treating anemia in patients with CKD not on dialysis, and is associated with significant improvements in functional status and quality of life."
|5.||darbepoetin alfa (Aranesp)FDA Link
07/01/2009 - "With several-fold more patient-years and a placebo arm, TREAT will provide a robust estimate of the safety and efficacy of darbepoetin alfa and generate prospective data regarding the risks of major cardiovascular and renal events in a contemporarily managed cohort of patients with type 2 diabetes, CKD, and anemia."
06/01/2008 - "Darbepoetin alfa is an erythropoiesis-stimulating agent that has been shown to be effective in treating anemia in patients with CKD (but not on dialysis) when administered using extended-dosing regimens. "
09/01/2006 - "The objective of this study was to determine if darbepoetin alfa administered at a reduced dosing frequency relative to the prior rHuEpo regimen is an effective and safe alternative for treating renal anemia in patients undergoing dialysis. "
05/01/2008 - "Darbepoetin alfa has the potential to simplify the treatment of CKD anemia with many advantages, including infrequent dosing, improved patient convenience and compliance, and decreased healthcare resource utilization. "
01/01/2005 - "Darbepoetin alfa is generally well tolerated, and clinical trials of 20-52 weeks' duration have demonstrated the efficacy of subcutaneous and intravenous administration at 1- or 2-week intervals in the initial treatment of anemia associated with CKD both in dialysis patients and in patients not yet on dialysis. "
12/01/2013 - "Treatment with erythropoiesis-stimulating agents (ESAs) is first-line treatment for the anemia of most patients with MDS. "
01/01/2010 - "The mainstay of treatment of anemia secondary to CKD has become erythropoiesis-stimulating agents (ESAs). "
01/01/2009 - "In these patients, erythropoiesis-stimulating agents (ESAs) are effective in managing anemia but there is an increased risk for thrombovascular events. "
06/01/2008 - "Several clinical trials have established the safety and efficacy of erythropoiesis-stimulating agents in correcting anemia in patients with HF. "
05/01/2013 - "Objective improvement in exercise testing and in patient-reported QoL confirms the clinical relevance of anemia correction with erythropoiesis-stimulating agents."
07/01/2002 - "Although not proven effective in this study, micronutrient supplementation should be prospectively assessed in HIV-infected infants as a means of preventing anemia."
07/25/2014 - "Nutrition policies aimed at ensuring optimal child and maternal micronutrient status and addressing the underlying risk factors for anemia are likely to result in improved health outcomes and a reduction in anemia. "
06/01/2010 - "A daily dose of "Sprinkles" (SuppleForte, Heinz, Canada), a micronutrient home supplementation, was proven effective for the treatment of anemia worldwide. "
12/01/2005 - "An integrated community approach including mass deworming, health education, and multi-micronutrient supplementation was very effective in reducing anemia in Cambodian schoolchildren and should be adopted on a larger scale."
01/01/2014 - "To address anemia and other micronutrient deficiencies, home-fortification with micronutrient powders (MNP) has been promoted among under-fives across Bangladesh along with the Global Alliance for Improved Nutrition (GAIN). "
05/01/1996 - "This effect may be mediated via an improved oxygen supply to the endothelial cells due to the amelioration of anemia by rHuEPO."
01/01/2014 - "To our knowledge, this is the first study to show that anemia caused altered oxygen extraction may have an effect on CO2-gap."
11/01/2013 - "The objective of this study was to investigate the effects of CPB and anemia on tissue oxygen tension (pO2) and blood flow in the renal cortex and medulla. "
03/01/2012 - "As central venous oxygen saturation (ScvO₂) may reflect imbalances in DO₂ and consumption (VO₂) the aim of this study was to investigate the value of ScvO₂ as an indicator of oxygen balance in isovolemic anemia. "
01/01/2012 - "Studies have generally shown that transfusion of red blood cells fails to increase oxygen uptake unless oxygen uptake/oxygen delivery dependency exists (e.g., severe anemia or strenuous exercise). "
04/01/1992 - "Human recombinant erythropoietin constitutes a remarkable improvement in the treatment of uraemic anemia. "
10/08/1988 - "Human recombinant erythropoietin (r-huEPO) is very effective in the treatment of anemia of hemodialyzed patients. "
06/01/1999 - "Our case report shows that recombinant erythropoietin gives good results in treatment of anemia: correction of anemia, improvement of general status and there is no need for frequent transfusions and thus there are less complications."
09/01/1995 - "Such strategies include collection and banking of autologous placental blood, administration of recombinant erythropoietin, innovations in blood banking practices, and improved definitions of the markers of anemia with more rigorous transfusion guidelines. "
03/01/2003 - "Human recombinant erythropoietin is the main treatment for anemia in renal patients. "
|10.||Ribavirin (Virazole)FDA LinkGeneric
08/01/2012 - "ITPA rs1127354 major type leads to significantly greater ribavirin-induced anemia than ITPA rs1127354 minor type between days 0 and 84. "
07/01/2005 - "Unless ribavirin can be shown to be effective against SARS-coronavirus, the risk of anemia posed by this drug argues against its use in SARS patients."
08/01/2012 - "Following these studies, ITPA gene variants were reported to affect ribavirin-induced anemia and therapeutic outcomes of CHC patients. "
10/01/2010 - "ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients."
11/01/2004 - "This study was conducted to identify the factors contributing to ribavirin-induced anemia. "
|1.||Drug Therapy (Chemotherapy)
07/01/2005 - "We conclude that darbepoetin alpha is a highly effective and well-tolerated drug in the treatment of chemotherapy-associated anemia. "
11/01/2015 - "In the subgroup of patients in complete remission 6 months after chemotherapy (n = 80), 6-month posttreatment anemia was significantly associated with reduced PFS (P = .046) but not OS (P = .062), and higher risk NCCN-IPI groups were significantly associated with both reduced PFS (P = .008) and OS (P = .017). "
12/01/2014 - "To investigate the clinical significance of chemotherapy-induced anemia and its recovery after completion of treatment, 87 patients in complete remission for ≥6 months from the time of the last cycle of R-CHOP were grouped and analyzed separately. "
04/01/2004 - "In patients who achieve complete remission after chemotherapy, anemia usually normalizes. "
07/01/2006 - "Patients receiving chemotherapy often experience chemotherapy-induced anemia, which contributes to a significant reduction in their quality of life. "
|2.||Renal Dialysis (Hemodialysis)
04/01/2007 - "This clinical study showed that Espogen has proven effective and safe for treatment of anemia in hemodialysis patients. "
02/01/1989 - "It is concluded that r-huEPO is very effective in treating the anemia of patients maintained on hemodialysis. "
05/01/1997 - "Our study suggests that improvement of anemia in patients on long-term hemodialysis by administration of EPO is associated with an improvement in hearing capacity in a significant number of patients. "
02/01/1993 - "Anemia contributes to significant debilitation in hemodialysis patients and, when reversed with epoetin therapy, results in significantly improved muscle function and endurance."
06/01/2009 - "LOH is a well tolerated hemodialysis option, associated with improved URR and better control of anemia."
|3.||Blood Transfusion (Blood Transfusions)
01/01/2013 - "Excessive blood loss and anemia still complicate most pregnancies in our practice and the mean decision-transfusion interval is unacceptably long with debilitating maternal morbidity and mortality that can be improved with safe and effective blood transfusion with minimal or no risk."
04/01/1999 - "Much of the increase in the patient's Hct vanishes at higher blood losses, and this therapy is most effective with blood loss of <4000 mL. EPO therapy alone may be most effectively used in patients with mild anemia who are undergoing routine surgical procedures that commonly require blood transfusion."
09/01/2005 - "Corticosteroid therapy and rinsed blood transfusion were very effective for anemia. "
03/01/1990 - "If proven effective in treating anemia in premature babies, r-HuEPO will be responsible for a major reduction in the use of blood transfusions in clinical neonatology. "
12/01/1996 - "A good outcome (neither recurrence of anemia nor blood transfusion requirements) was observed in 12 patients. "
01/01/1987 - "Unique features of this case include the use of PE to avoid splenectomy, the complete and permanent clearance of detectable antibody following PE, and the rapid correction of anemia by infusing packed erythrocytes during the procedure. "
04/01/1983 - "Splenectomy induced marked improvement of anemia."
01/01/1987 - "The benefit of splenectomy for treatment of splenic hyperfunction depends on the stimulus to hyperfunction and may not be beneficial for patients with refractory autoimmune anemias."
01/01/1986 - "Splenectomy may be beneficial in anemias with erythrocyte rigidification if clinical condition so requires (repeated transfusions, aplastic and hemolytic crises). "
01/01/1986 - "Although they are significantly benefited by splenectomy, their anemia is not completely corrected. "
|5.||Transplantation (Transplant Recipients)
01/01/2014 - "Anemia improved significantly by 3 months after transplantation. "
01/01/2014 - "The mean pretransplantation Hb level was 10.4 g/dL, whereas Hb levels at 6, 12, and 24 months after transplantation were significantly increased to 11.6, 12.2, and 12.4 g/dL, respectively, suggesting an improvement in anemia after the transplantation. "
01/01/2007 - "Erythropoietinis effective and safe in correcting anemia during both early and late post-transplantation period. "
02/01/2005 - "Treatment with SFG appears to yield some improvement in anemia in renal transplant recipients, but the paucity of published information on this topic highlights the need for stronger data, particularly with respect to pediatric patients."
06/01/2011 - "The aim of this study was to analyze the prevalence and efficacy of renal anemia treated with epoetin in maintenance kidney transplant recipients in Slovenia. "